Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerResearch in context

• Main Authors: Yuankai Shi (Author), Gongyan Chen (Author), Xiang Wang (Author), Yunpeng Liu (Author), Lin Wu (Author), Yanrong Hao (Author), Chunling Liu (Author), Shuyang Zhu (Author), Xiaodong Zhang (Author), Yuping Li (Author), Jiwei Liu (Author), Lejie Cao (Author), Ying Cheng (Author), Hui Zhao (Author), Shucai Zhang (Author), Aimin Zang (Author), Jiuwei Cui (Author), Jian Feng (Author), Nong Yang (Author), Jie Hu (Author), Fei Liu (Author), Yong Jiang (Author), Nan Ge (Author)
• Format: Book
• Published: Elsevier, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Furmonertinib showed superior efficacy compared with gefitinib as first-line therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in the FURLONG study. Here we present prespecified secondary endpoints of patient-re...